According to the Zhitong Finance App, Jingyou Pharmaceutical (00858) announced that 9.14% of the total issued share capital of Changchun Jingyou has been cancelled. All conditions have been met. The share repurchase and share cancellation were completed on June 19, 2023. Immediately after completion and on the date of this announcement, the total number of issued shares of Changchun Elite was reduced from 50 million to 45.43 million shares, and its registered capital was reduced from RMB 50 million to RMB 45.43 million after the shares were cancelled. As a result, the group's equity in Changchun Jingyou increased from 73.11% to 80.46%. Changchun Jingyou is still an indirect non-wholly owned subsidiary of the Group and the financial results (including profits, assets and liabilities) of Changchun Jingyou will be included in the Group's financial statements.
精优药业(00858)：长春精优完成回购注销457万股 公司持股增至80.46%
Jingyou Pharmaceutical (00858): Changchun Jingyou completed the repurchase and cancellation of 4.57 million shares, and the company's shareholding increased to 80.46%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.